[Carbimazole therapy in Basedow's disease: therapy results in individual dosage adjustment].
We analyzed the results of 85 treatments with carbimazol in 71 patients with Graves' disease. The initial dose ranged from 45 to 60 mg/day, which was gradually reduced to the lowest possible maintenance dose; the mean treatment period was 17 months. All patients achieved euthyroid function after 12 weeks at the latest. Normalization of the pituitary TSH-reserve occurred late (after 6-12 months in most cases). 60% of the patients treated for the first time (n = 58) and 59% of the whole group remained in remission. The maintenance dose of carbimazol had no effect on the rate of remission. It is interesting to note that in 66% of the patients a very low dose (less than or equal to 5 mg/day) was fully effective and resulted in a remission rate of 54%. Therefore, the dose should always be reduced individually. Relapses occurred within the first year after the end of treatment in 77% of the cases, but were also observed after 2-3 years. Hence follow-up should be continued after cessation of therapy.
Trabucco
P
P
Abteilung Endokrinologie und Stoffwechsel und Medizinische Poliklinik, Universitätskliniken, Kantonsspital Basel.
Engler
H
H
Ryff-de Lèche
A
A
Althaus
B
B
Staub
J J
JJ
D000328:Adult; D002231:Carbimazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006111:Graves Disease / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D013960:Thyroid Function Tests
D002231:Carbimazole
Carbimazol-Therapie beim Morbus Basedow: Therapieerfolg bei individueller Dosisanpassung.